Procept Biorobotics (PRCT) Osake Kurssi
Procept Biorobotics Kurssi
Liikevaihto on kasvanut 95,5 % vuodessa viimeisten 6 vuoden aikana 304,47 M USD:een. Procept Bioroboticsn nettomarginaali on nyt −31,4 %, noussut −208,8 %:sta muutama vuosi sitten. Analyytikoiden mediaanitavoitehinta on 20,50 USD, eli yli nykyhintaa 14,5 %. 21 analyytikosta 10 suosittaa ostoa — kokonaiskonsensus on Pidä.
Procept Biorobotics osakekurssi
Procept Biorobotics liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Procept Biorobotics -osakkeesta
The business model of PROCEPT BioRobotics Corp. is focused on developing and commercializing innovative surgical technologies. The company specializes in the design and manufacturing of the AquaBeam® System, a robotic surgical platform used for treating patients with prostate conditions. This state-of-the-art technology combines the precision of a robotic arm with the benefits of water-jet technology to provide minimally invasive procedures with increased accuracy and efficiency. PROCEPT BioRobotics Corp. aims to improve patient outcomes by delivering advanced solutions in the field of urology through their AquaBeam® System, positioning themselves as leaders in robotic-assisted surgeries for prostate treatment.
PROCEPT BioRobotics Corp is primarily active in the medical device and healthcare industries.
The main competitors of PROCEPT BioRobotics Corp in the market include companies such as Intuitive Surgical, Inc., Medtronic Plc, and Johnson & Johnson.
PROCEPT BioRobotics Corp is a renowned medical device company specializing in surgical robotics. Founded in 2002, the company has made significant strides in improving the treatment of Benign Prostatic Hyperplasia (BPH). PROCEPT BioRobotics Corp developed the revolutionary Aquablation® therapy, which utilizes advanced robotic technology to precisely and efficiently remove prostate tissue without causing significant side effects. This minimally invasive procedure has garnered recognition for its effectiveness in improving the quality of life for patients suffering from BPH. With a strong focus on innovation and patient care, PROCEPT BioRobotics Corp continues to lead the way in robotic surgical solutions for urologic conditions.
PROCEPT BioRobotics Corp has achieved several significant milestones. The company developed and gained regulatory approval for its groundbreaking Aquablation therapy, a minimally invasive treatment for benign prostatic hyperplasia (BPH). They successfully launched their flagship product, the AquaBeam® Robotic System, in the US and other international markets. PROCEPT BioRobotics Corp expanded its global presence by establishing strategic partnerships and growing its distribution network. They have consistently demonstrated strong clinical outcomes, with numerous peer-reviewed publications supporting the effectiveness and safety of Aquablation therapy. The company's milestones highlight its commitment to revolutionizing BPH treatment and improving patient outcomes worldwide.
PROCEPT BioRobotics Corp is primarily present in the United States.
PROCEPT BioRobotics Corp is committed to its core values of innovation, collaboration, and patient-centricity. With a corporate philosophy focused on developing transformative solutions for patients and healthcare providers, the company aims to revolutionize the field of surgical robotics. PROCEPT BioRobotics Corp strives to enhance patient outcomes by offering its advanced Aquablation® technology, enabling precise and personalized therapy for patients with urologic conditions. By incorporating cutting-edge robotics, the company prioritizes effective treatments and improved patient experiences. Through continuous research, development, and partnerships, PROCEPT BioRobotics Corp dedicates itself to pushing boundaries and revolutionizing the healthcare industry.
Analyytikot asettavat tällä hetkellä Procept Biorobotics-osakkeelle keskimääräisen tavoitehinnan 22,13 USD (mediaani: 20,50 USD), mikä merkitsee +20,4 % viimeisimpään hintaan verrattuna. Konsensus perustuu 21 analyytikkoarvioon.
21 analyytikkoa arvioi tällä hetkellä Procept Biorobotics-osaketta: 10 suosittaa ostoa, 10 pitoa ja 1 myyntiä. Vuodelle 2026 analyytikot odottavat Procept Biorobotics-yhtiöltä 395,41 M USD liikevaihtoa ja −1,65 USD osakekohtaista tulosta.
Nykyisellä valuuttakurssilla Procept Biorobotics-osake noteerataan hintaan 15,97 EUR (17,90 USD).
Procept Biorobotics-osake (PRCT) on listattuna 1 pörssissä, muun muassa: NASDAQ (PRCT).
PROCEPT BioRobotics Corp is a global provider of innovative robotic solutions for urological surgeries. The company aims to improve patient's quality of life while increasing the efficiency of surgeons. PROCEPT BioRobotics Corp's main product is the Aquablation® System, which uses robotic technology to treat benign prostatic hyperplasia. The Aquablation® System offers numerous advantages such as faster recovery, reduced risk of complications, and immediate symptom relief. The company also offers training and education services to healthcare professionals. PROCEPT BioRobotics Corp follows a "Razor-and-Blades" business model, offering the Aquablation® System at an affordable price while generating revenue from the regular supply of consumables. The company prioritizes regulatory compliance and has implemented a global quality management system. In summary, PROCEPT BioRobotics Corp is a leading company in the field of robotic urology, providing an excellent alternative to traditional surgical treatments.
odotettu liikevaihto Procept Biorobotics on 395,41 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
odotettu voitto Procept Biorobotics on −92,78 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Procept Biorobotics:n hinta-voitto-suhde (P/E) on tällä hetkellä −10,82. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Procept Biorobotics-osakkeen arvostusta.
Procept Biorobotics:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,54. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Procept Biorobotics-osakkeen arvostuskennuslukuna.
Procept Biorobotics:n Eulpool-laatuscore on 2/10.
Procept Biorobotics:n ISIN on US74276L1052. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Procept Biorobotics:n ticker on PRCT. Tämä pörssinoteeraus käytetään Procept Biorobotics-osakkeiden kauppaan pörssissä.
Procept Biorobotics osake
Procept Biorobotics vertaisryhmä
Procept Biorobotics Ticker
Procept Biorobotics FIGI
Kaikki tunnusluvut ja syvällinen analyysi Procept Biorobotics:sta
Meidän osakeanalyysimme Procept Biorobotics-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Procept Biorobotics:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: